1. SAMHSA is missing opportunities to better monitor access to medication-assisted treatment through the buprenorphine waiver program Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, June 2021 Subject(s): United States Substance Abuse and Mental Health Services AdministrationBuprenorphine -- supply & distributionGovernment RegulationOpioid EpidemicUnited StatesUnited States. Department of Health and Human Services
